Compare SOTK & ACRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SOTK | ACRV |
|---|---|---|
| Founded | 1975 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 68.8M | 47.6M |
| IPO Year | 1995 | 2022 |
| Metric | SOTK | ACRV |
|---|---|---|
| Price | $4.22 | $1.63 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 6 |
| Target Price | N/A | ★ $13.00 |
| AVG Volume (30 Days) | 28.1K | ★ 852.9K |
| Earning Date | 01-01-0001 | 04-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 13.14 |
| EPS | ★ 0.08 | N/A |
| Revenue | ★ $20,504,381.00 | N/A |
| Revenue This Year | $4.02 | N/A |
| Revenue Next Year | $10.95 | $805.34 |
| P/E Ratio | $51.75 | ★ N/A |
| Revenue Growth | ★ 4.08 | N/A |
| 52 Week Low | $3.23 | $1.05 |
| 52 Week High | $5.15 | $5.65 |
| Indicator | SOTK | ACRV |
|---|---|---|
| Relative Strength Index (RSI) | 53.57 | 47.09 |
| Support Level | $3.87 | $1.49 |
| Resistance Level | $4.30 | $1.86 |
| Average True Range (ATR) | 0.24 | 0.12 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 44.33 | 46.07 |
Sono-Tek Corp design and manufacture of ultrasonic coating systems for applying precise, thin film coatings to add functional properties, protect or strengthen surfaces on parts and components for the microelectronics/electronics, alternative energy, medical, industrial and emerging research & development/other markets. The company design and manufacture custom-engineered ultrasonic coating systems incorporating its patented technology, in combination with strong applications engineering knowledge, to assist its customers in achieving their desired coating solutions.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.